StockChaser

What you’ll find inside our private group: -35+ fundamental analyses -420+ charts shared -Weekly deep-dive recaps -Long-term analysis -Educational content Built so you learn, understand, and apply. $20/month. No hidden fees 👉 patreon.com/c/StockChaser_

@DCDOWORK @NIONenad EOY

@StockChaser_ @NIONenad realistic time frame?

$NIO looking VERY good right now 200 MA flipped into support Next target: $12.43

Been a while since I talked about $RDW Ever since it hit our wave 5 target and rejected off the wedge, we moved to the sidelines Price retraced to the 0.618 fib level after the rejection From here, the main technical focus is the 50MA which has been acting as meaningful resistance recently Fundamentally, the story has continued to get stronger over the last month: • Redwire introduced ELSA, a new low-mass solar array built for mass-produced satellites • NASA added $4M more to Redwire’s ISS drug-development work using PIL-BOX • Redwire won a $12.8M contract to deliver ELSA solar arrays to Moog for a national-security LEO mission • Redwire’s imaging and navigation tech will fly on NASA’s Artemis II mission • ESA selected Redwire for its QKDSat quantum-secure satellite project However, macro remains the main focus

$IBRX has one of the most interesting biotech theses right now Curing cancer Not through chemotherapy, but through immunotherapy They use your own immune system to attack the tumors which results in: • Less damage to the body • Potentially lower relapse risk • Potentially more durable responses Their drug ANKTIVA is already approved in: • US • European Commission • UK • Saudi Arabia • Etc. In total, the therapy is now authorized in approximately 34 countries globally with the recent Macao approval Today it’s primarily used for bladder cancer (already 700% YoY growth) But the real opportunity is expansion • Saudi Arabia already granted accelerated approval for lung cancer combination therapy • FDA acknowledged the papillary-only sBLA resubmission • NCCN added ANKTIVA + BCG for papillary-only NMIBC If additional indications succeed → the market expands dramatically But no biotech thesis comes without risks: • Very high valuation: 66x P/S • FDA warning regarding promotional claims that suggested ANKTIVA could work beyond its approved label The real thesis: ANKTIVA isn’t designed to be just another cancer drug The bull case is that it could become a backbone immunotherapy that can be combined with other treatments

@BlackPantherCap Completly agree

@StockChaser_ Without doubt. But crossing those milestones just became 3x harder mate

I have 19,741 followers. Two months ago: 289 new followers/day. Now: 86/day. The math changed. Goal: 100K followers. Before: 289 days (0.8 years) Now: 958 days (2.7 years) Same goal. Different timeline. X just made growth 3x harder. Lower reach per post. Slower follower velocity. Higher friction in the loop. From a platform lens, this extends the creator lifecycle. From a creator lens, it compresses motivation. From a business perspective, I’m not sure if this is lifecycle extension or churn risk? What’s your thoughts?

@Dansnapd nope

@StockChaser_ Clearly $msos

Challenge 👇 Guess the chart It’s looking very good right now Let’s see who gets it

@gerardoah189 nope

@StockChaser_ AMC

@CAccumulation nope

@StockChaser_ $NATGAS

@Tesla4all42069 nope

@StockChaser_ Descending channel on $tsla?

@DLedererova yes

@StockChaser_ Is it daily?

No rest days here on X or Patreon Same mindset you should have, whether you’re just starting or already big No stopping. Discipline is everything That’s how you stay ahead of the market Are you consistent? 👇

Analysts rate $ONDS a Strong Buy 👀 Avg target: $19.78 High: $25 We’re approaching a key zone on the chart Things could start getting even more interesting

@roeiharush why don’t you like it

@StockChaser_ Looking very good? WTF you talk about

@sikmynd333 nope

@StockChaser_ $HOOD

@Niostof Nope, it’s not $NIO

@StockChaser_ NIO

@Slowhorse99 Nope

@StockChaser_ $MBLY

@LongGameEquity True

@StockChaser_ High beta 👀

The magic six ✨ $ZETA $ETH $MELI $RDDT $ONDS $SOFI Not everyone will hold them long enough

I’m thinking: early setups + entries + risk management

Close to 2,000 verified followers Thinking about launching a subscription here on X What would you like to see? More charts, fundamentals, hidden gems?